Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease
NCT00092222Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2004
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of zidovudine and valganciclovir in Multicentric Castleman disease (MCD) (6 arms), sponsored by National Cancer Institute. Primary endpoint: Describe natural history. Started Oct 2004; status: active, not recruiting.
02
Drugs
zidovudinevalganciclovir
03
Conditions
Multicentric Castleman disease (MCD)
Beyond the preview
Go deeper on NCT00092222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00092222.